SIGLEC10 and cancer: Then, three-armed cancer-targeting OAds were developed: OAd-SIRPα-Fc and OAd-Siglec10-Fc, which expressed SIRPα-Fc or Siglec10-Fc, respectively, to target macrophages to restore the phagocytic capabilities of these cells, and OAd-TIGIT-Fc, which secreted TIGIT-Fc to reactivate T cells (Fig. 2a).